Eyenovia Inc (EYEN) USD0.0001

Sell:$1.74Buy:$1.77$0.26 (12.81%)

Prices delayed by at least 15 minutes
Sell:$1.74
Buy:$1.77
Change:$0.26 (12.81%)
Prices delayed by at least 15 minutes
Sell:$1.74
Buy:$1.77
Change:$0.26 (12.81%)
Prices delayed by at least 15 minutes

Company Information

About this company

Eyenovia, Inc. is an ophthalmic technology company. The Company is developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform. The Optejet is especially useful in chronic front-of-the-eye diseases due to its potential for superior compliance versus standard eye drops. The Company’s commercial portfolio includes clobetasol propionate ophthalmic suspension, 0.05%, for post-surgical pain and inflammation, and Mydcombi for mydriasis. Mydcombi is an FDA-approved fixed combination of the two pupil dilation drugs, tropicamide and phenylephrine, delivered with its Optejet technology. The product is indicted to induce mydriasis (pupil dilation) for routine diagnostic procedures and in conditions where short-term pupil dilation is desired. MicroLine is its investigational proprietary microdosed version of pilocarpine, an ophthalmic medication that can dose-dependently induce miosis, or contraction of the pupil.

Key people

Michael M. Rowe
President, Chief Executive Officer, Principal Financial Officer, Treasurer, Company Secretary, Director
Bren Kern
Chief Operating Officer
Charles E. Mather
Independent Chairman of the Board
Tsontcho Ianchulev
Director
Michael Geltzeiler
Independent Director
Rachel Jacobson
Independent Director
Ram Palanki
Independent Director
Click to see more

Key facts

  • EPIC
    EYEN
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US30234E2037
  • Market cap
    $4.04m
  • Employees
    13
  • Shares in issue
    2.88m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.